首页> 美国卫生研究院文献>Gastroenterology Hepatology >Determination of Serum Antibodies to Clostridium difficile Toxin B in Patients with Inflammatory Bowel Disease
【2h】

Determination of Serum Antibodies to Clostridium difficile Toxin B in Patients with Inflammatory Bowel Disease

机译:炎性肠病患者难辨梭状芽孢杆菌毒素B血清抗体的测定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clostridium difficile infection has increased in prevalence among patients with inflammatory bowel disease (IBD). Serum antibodies against C. difficile toxins have been detected in susceptible populations and may be protective; however, such antibodies have not been previously characterized in IBD patients. This study measured immunoglobulin G antibody levels to C. difficile toxin B in serum from IBD patients in remission and IBD patients in relapse. IBD patients demonstrated significantly higher antibody levels than non-IBD patients. In addition, a higher proportion of IBD patients in remission had positive antibody levels compared to IBD patients in relapse. Further characterization of antibody responses may elucidate understanding of susceptibility to C. difficile infection among IBD patients.
机译:炎性肠病(IBD)患者的艰难梭菌感染率有所增加。在易感人群中已检测到针对艰难梭菌毒素的血清抗体,这些抗体可能具有保护作用;然而,这种抗体先前并未在IBD患者中表征。这项研究测量了缓解期IBD患者和复发期IBD患者血清中针对艰难梭菌毒素B的免疫球蛋白G抗体水平。 IBD患者的抗体水平明显高于非IBD患者。另外,与复发的IBD患者相比,缓解的IBD患者比例更高。抗体反应的进一步特征可以阐明对IBD患者中艰难梭菌感染的敏感性的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号